A Case of Acute Myeloid Leukemia Harboring a Rare Three-Way Translocation T(5;7;7) Involving the Gene and Successfully Treated with Imatinib

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Dec 3

PMID 34858057

Authors

Azra Borogovac

Kamal Kant Sahu

Ganesh Kumar Vishwanathan

Patricia Minehart Miron

Jan cerny

Affiliations

Soon will be listed here.

Abstract

Platelet-derived growth factor-beta () gene maps for the receptor tyrosine kinase PDGRFβ. gene fusions have been implicated in multiple myeloid and lymphoid neoplasms and have shown exquisite sensitivity to tyrosine kinase inhibitors. We report a case of a 29-year-old male who presented with acute myeloid leukemia who was eventually found to harbor a unique three-way translocation t(5;7;7)(q33.2;q32;q11.2) involving the gene. The patient initially achieved a complete response after induction with daunorubicin and cytarabine, but when he returned for consolidation, his white cell count had increased, and he was found to have an underlying myeloproliferative neoplasm. He was given consolidation with high-dose cytarabine and imatinib with excellent response, and ultimately received a matched unrelated donor transplant. The patient remains in remission to this day more than eight years later.

References

Appiah-Kubi K, Lan T, Wang Y, Qian H, Wu M, Yao X . Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies. Crit Rev Oncol Hematol. 2016; 109:20-34. DOI: 10.1016/j.critrevonc.2016.11.008. View

Vega F, Medeiros L, Bueso-Ramos C, Arboleda P, Miranda R . Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015; 144(3):377-92. DOI: 10.1309/AJCPMORR5Z2IKCEM. View

Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini C . NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. Leukemia. 2016; 31(1):237-240. PMC: 5220134. DOI: 10.1038/leu.2016.250. View

Tran T, Nguyen J, Stecula A, Akutagawa J, Moorman A, Braun B . The T681I mutation is highly resistant to imatinib and dasatinib and detectable in clinical samples prior to treatment. Haematologica. 2021; 106(8):2242-2245. PMC: 8327742. DOI: 10.3324/haematol.2020.261354. View

Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A . Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013; 27(11):2254-6. DOI: 10.1038/leu.2013.129. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Demoulin J, Montano-Almendras C . Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res. 2012; 2(1):44-56. PMC: 3301440. View

Shimomura Y, Maruoka H, Ishikawa T . Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia. Int J Hematol. 2016; 105(5):697-701. DOI: 10.1007/s12185-016-2167-z. View

Bell G, Padron E . Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling. Leuk Res Rep. 2015; 4(2):70-1. PMC: 4672079. DOI: 10.1016/j.lrr.2015.07.002. View

10.

Reiter A, Gotlib J . Myeloid neoplasms with eosinophilia. Blood. 2016; 129(6):704-714. DOI: 10.1182/blood-2016-10-695973. View

11.

Kazlauskas A . PDGFs and their receptors. Gene. 2017; 614:1-7. PMC: 6728141. DOI: 10.1016/j.gene.2017.03.003. View

12.

Tokita K, Maki K, Tadokoro J, Nakamura Y, Arai Y, Sasaki K . Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia. 2006; 21(1):190-2. DOI: 10.1038/sj.leu.2404397. View

13.

David M, Cross N, Burgstaller S, Chase A, Curtis C, Dang R . Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2006; 109(1):61-4. DOI: 10.1182/blood-2006-05-024828. View

14.

Bain B . Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica. 2010; 95(5):696-8. PMC: 2864371. DOI: 10.3324/haematol.2009.021675. View

15.

Pozdnyakova O, Orazi A, Kelemen K, King R, Reichard K, Craig F . Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. Am J Clin Pathol. 2020; 155(2):160-178. DOI: 10.1093/ajcp/aqaa208. View

16.

Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F . HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 2004; 64(8):2649-51. DOI: 10.1158/0008-5472.can-03-4026. View

17.

Wu E, Palmer N, Tian Z, Moseman A, Galdzicki M, Wang X . Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One. 2008; 3(11):e3794. PMC: 2582946. DOI: 10.1371/journal.pone.0003794. View

18.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang T . Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017; 96(9):1463-1470. DOI: 10.1007/s00277-017-3067-x. View

19.

Wenger T, Bly R, Wu N, Albert C, Park J, Shieh J . Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A. 2020; 182(7):1576-1591. DOI: 10.1002/ajmg.a.61615. View

20.

Cheah C, Burbury K, Apperley J, Huguet F, Pitini V, Gardembas M . Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014; 123(23):3574-7. PMC: 4047496. DOI: 10.1182/blood-2014-02-555607. View